[
    {
        "id": "osp-11350",
        "type": "article-journal",
        "title": "Cushing’s Disease: Sustained remission in five cases induced by medical therapy with the dopamine agonist cabergoline",
        "author": [
            {
                "family": "Elshafie",
                "given": "Omayma"
            },
            {
                "family": "Osman",
                "given": "Anjum"
            },
            {
                "family": "Al-Mamari",
                "given": "Fatima"
            },
            {
                "family": "Ali",
                "given": ""
            },
            {
                "family": "Woodhouse",
                "given": "NJY"
            }
        ],
        "URL": "https://omanscience.com/ar/articles/cushing-s-disease-sustained-remission-in-five-cases-induced-by-medical-therapy-with-the-dopamine-agonist-cabergoline",
        "language": "en",
        "issued": {
            "date-parts": [
                [
                    2025
                ]
            ]
        },
        "container-title": "Sultan Qaboos University Medical Journal",
        "volume": "12",
        "issue": "4",
        "page": "493-497",
        "DOI": "10.18295/2075-0528.1411",
        "publisher": "Sultan Qaboos University",
        "ISSN": "2075-051X",
        "abstract": "We report five cases of Cushing’s disease where the patients were given a therapeutic trial of cabergoline. Morning serum cortisol, adrenocorticotrophic hormone (ACTH), and sleeping cortisol concentrations were significantly raised. Magnetic resonance imaging (MRI) scans revealed pituitary microadenomas in 3 patients but were normal in the others. Ectopic ACTH production was excluded in the 2 patients with normal MRI scans. All were given a therapeutic trial of cabergoline (1 mg daily). Four patients responded with a prompt fall in serum cortisol levels and had a sustained clinical and biochemical remission for 378, 44, 28 and 14 days, respectively. One patient failed to respond. In conclusion, we suggest that all patients with Cushing’s disease should undergo a therapeutic trial of cabergoline. Responders can then be prepared for surgery or, if needed, treated medically in the long term."
    }
]